Selenium and Triple Negative Breast Cancer
Acta Medica Academica · 2024
DOI: 10.5644/ama2006-124.450 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Medica Academica, 2024. Verfasst von Despoina Sidira und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, National and Kapodistrian University of Athens, Athens, Greece. despinasidirag@gmail.com. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Selenium. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The deadliest, most dangerous subtype of breast cancer is triple-negative, which lacks treatment targets and accounts for 30% of all breast cancer-related deaths worldwide. TNBC is characterized by the expression of no estrogen, proges- terone, or human epidermal growth factor 2 receptors. This suggests that new treatment modalities with fewer adverse effects are required.
Objective
The aim of the present study was to investigate the therapeutic potential of selenium compounds as an adjuvant therapy for Triple Negative Breast Cancer (TNBC), either on their own or in conjunction with nutritional supplements and chemotherapy medications.
Methods
Using the keywords “selenium” and “triple negative breast cancer”, a thorough search was conducted in the PubMed database, yielding 23 articles. The following factors were taken into consideration for inclusion: studies using TNBC cell culture lines or in vivo tumors/specimens; full-text articles from the PubMed database; studies published in the English language; experiments with statistically significant results; and selenium used alone or in combination with other antioxidants or chemotherapy. This led to the evaluation of 13 articles in this review.
Results
The results show that selenium therapy increased the anti-cancer drug’s effects and produced tumor cytotoxicity, while reducing the cellular features of the cancer (hyperproliferation, growth, and metastasis).
Discussion
This study evaluated the various selenium compounds tested, the cell lines and model organisms used, the assays performed, and the cellular pathways affected.
Conclusion
Examining the possible benefits of selenium in TNBC treatment highlights the need for more studies to confirm selenium compounds as viable co-therapeutic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical School, National and Kapodistrian University of Athens, Athens, Greece. despinasidirag@gmail.com.
- Medical School, National and Kapodistrian University of Athens, Athens, Greece.
- Department of Anatomy, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Zitieren
APA
Sidira, D., Siafaka, A., Chrysikos, D., Papadopoulos, G., Stratopoulos, E., & Filippou, D. (2024). Selenium and Triple Negative Breast Cancer. Acta Medica Academica. https://doi.org/10.5644/ama2006-124.450
Vancouver
Sidira D, Siafaka A, Chrysikos D, Papadopoulos G, Stratopoulos E, Filippou D. Selenium and Triple Negative Breast Cancer. Acta Medica Academica. 2024. doi:10.5644/ama2006-124.450
BibTeX
@article{Sidira2024,
author = {Sidira, Despoina and Siafaka, Angeliki and Chrysikos, Dimosthenis and Papadopoulos, Georgios and Stratopoulos, Epameinondas and Filippou, Dimitrios},
title = {Selenium and Triple Negative Breast Cancer},
journal = {Acta Medica Academica},
year = {2024},
doi = {10.5644/ama2006-124.450}
}
EUVIMED